Sit Investment Associates’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18.8M | Sell |
99,154
-660
| -0.7% | -$124K | 0.36% | 68 |
|
|
2026
Q1 | $19.7M | Sell |
99,814
-12,524
| -11% | -$2.41M | 0.4% | 60 |
|
|
2025
Q4 | $20.7M | Sell |
112,338
-7,085
| -6% | -$1.24M | 0.41% | 59 |
|
|
2025
Q3 | $18.3M | Sell |
119,423
-8,549
| -7% | -$1.29M | 0.37% | 60 |
|
|
2025
Q2 | $17.9M | Buy |
127,972
+8,765
| +7% | +$1.23M | 0.38% | 63 |
|
|
2025
Q1 | $17.5M | Buy |
119,207
+35,782
| +43% | +$5.18M | 0.41% | 67 |
|
|
2024
Q4 | $10.9M | Sell |
83,425
-36,525
| -30% | -$5.11M | 0.25% | 109 |
|
|
2024
Q3 | $18.7M | Sell |
119,950
-7,135
| -6% | -$1.15M | 0.42% | 66 |
|
|
2024
Q2 | $19.8M | Sell |
127,085
-4,078
| -3% | -$614K | 0.46% | 65 |
|
|
2024
Q1 | $17.8M | Sell |
131,163
-7,792
| -6% | -$1.03M | 0.41% | 72 |
|
|
2023
Q4 | $18.7M | Sell |
138,955
-1,670
| -1% | -$217K | 0.46% | 57 |
|
|
2023
Q3 | $19M | Buy |
140,625
+5,804
| +4% | +$793K | 0.52% | 52 |
|
|
2023
Q2 | $19.3M | Sell |
134,821
-92
| -0.1% | -$13.5K | 0.5% | 49 |
|
|
2023
Q1 | $18.7M | Buy |
134,913
+4,352
| +3% | +$586K | 0.51% | 46 |
|
|
2022
Q4 | $17.7M | Sell |
130,561
-7,430
| -5% | -$932K | 0.5% | 48 |
|
|
2022
Q3 | $15.1M | Buy |
137,991
+6,230
| +5% | +$790K | 0.45% | 59 |
|
|
2022
Q2 | $17.4M | Sell |
131,761
-11,837
| -8% | -$1.55M | 0.53% | 47 |
|
|
2022
Q1 | $19.1M | Sell |
143,598
-280
| -0.2% | -$33.6K | 0.51% | 51 |
|
|
2021
Q4 | $16.8M | Sell |
143,878
-5,040
| -3% | -$593K | 0.39% | 74 |
|
|
2021
Q3 | $17.9M | Buy |
148,918
+18,305
| +14% | +$2.13M | 0.46% | 56 |
|
|
2021
Q2 | $15.6M | Sell |
130,613
-6,088
| -4% | -$668K | 0.39% | 72 |
|
|
2021
Q1 | $13.6M | Buy |
136,701
+8,033
| +6% | +$808K | 0.36% | 77 |
|
|
2020
Q4 | $12.9M | Buy |
128,668
+3,435
| +3% | +$364K | 0.35% | 81 |
|
|
2020
Q3 | $13.7M | Buy |
125,233
+3,100
| +3% | +$345K | 0.4% | 68 |
|
|
2020
Q2 | $12.9M | Sell |
122,133
-20,800
| -15% | -$2.15M | 0.41% | 70 |
|
|
2020
Q1 | $12.8M | Buy |
142,933
+1,025
| +0.7% | +$96.5K | 0.48% | 55 |
|
|
2019
Q4 | $14.2M | Buy |
141,908
+2,438
| +2% | +$230K | 0.4% | 64 |
|
|
2019
Q3 | $12.4M | Buy |
139,470
+32,100
| +30% | +$2.78M | 0.38% | 78 |
|
|
2019
Q2 | $8.86M | Buy |
107,370
+97,970
| +1,042% | +$7.68M | 0.27% | 111 |
|
|
2019
Q1 | $760K | Buy |
9,400
+7,150
| +318% | +$564K | 0.02% | 363 |
|
|
2018
Q4 | $171K | Buy |
+2,250
| New | +$176K | 0.01% | 470 |
|
Other funds holding AZN
EP
IA
Sit Investment Associates's AZN Position: Q2 2026 in Review
Sit Investment Associates reduced its AstraZeneca (AZN) stake by 0.66% in Q2 2026, selling an estimated $124K and leaving 99,154 shares worth $18.8M. The position accounts for 0.36% of the portfolio, ranked #68.
Sit Investment Associates first reported a position in AZN in Q4 2018 and has held it in 31 quarters since. The position peaked at $20.7M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Sit Investment Associates held 99,154 shares of AstraZeneca worth $18.8M as of Q2 2026.
- Sit Investment Associates sold 660 AstraZeneca shares in Q2 2026, an estimated $124K.
- AstraZeneca made up 0.36% of Sit Investment Associates's portfolio in Q2 2026, its #68 holding.
- Sit Investment Associates first reported a position in AstraZeneca in Q4 2018 and has held it in 31 quarters since.
- Sit Investment Associates's AstraZeneca position peaked at $20.7M in Q4 2025.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Sit Investment Associates's 13F filing for Q2 2026, filed 12 Aug 2026.